Market Overview

UPDATE: Morgan Stanley Upgrades Alkermes plc to Overweight on New Pipeline Opportunities

Related ALKS
15 Biggest Mid-Day Gainers For Friday
Mid-Day Market Update: Alkermes Surges Following Positive Data For Depression Drug Trial; Stone Energy Shares Slide
Alkermes buying ripples out to Cerecor; shares up 17% (Seeking Alpha)

Morgan Stanley upgraded Alkermes plc (NASDAQ: ALKS) from Equal-weight to Overweight and raised the price target from $21.00 to $26.00.

Morgan Stanley noted, "We anticipate improving investor perception as Alkermes transitions from being an outsourced drug delivery tech co. to an innovation engine with higher-value internal candidates. … We added a key new pipeline drug (3831 for schizophrenia) due to new disclosure Jan. 4, and we have greater conviction that Alkermes can develop new drugs to offset patent expirations in 2019 and beyond."

Alkermes plc closed at $21.61 on Wednesday.

Latest Ratings for ALKS

Oct 2016JP MorganUpgradesNeutralOverweight
Oct 2016Leerink SwannAssumesOutperform
Sep 2016CitigroupMaintainsNeutral

View More Analyst Ratings for ALKS
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings


Related Articles (ALKS)

View Comments and Join the Discussion!